Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program
Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9. The approval enables initiation of the clinical development program for ZH9 in the U.S., focusing on patients with non-muscle invasive bladder cancer.
"The FDA’s approval of our IND application is an important milestone and a clear recognition of the preclinical data already generated for ZH9,” stated Prokarium’s CEO, Kristen Albright, PharmD. “Importantly, it also validates the innovative design of the PARADIGM-1 study, paving the way for collaboration with top-tier research centers in the U.S.”
“Urologists are excited to see the emergence of new therapies in clinical development for bladder cancer patients,” stated Sam S. Chang, MD, Chief Surgical Officer at the Vanderbilt Ingram Cancer Center. “The urgent and continuous need to prevent bladder cancer recurrence, especially given the ongoing shortage of BCG, the standard treatment option for high-risk patients, makes the development of innovative alternatives a matter of utmost importance.”
In a strategic move, Prokarium strengthens their leadership team with the appointment of Dara Henry, PhD, as Chief Operating Officer. Dara brings over two decades of experience in biotech and large pharma. His recent role as an entrepreneur-in-residence at Evotec, and prior senior positions in operations and business development at Achilles Therapeutics and GlaxoSmithKline, demonstrate his commitment to advancing biopharmaceutical innovation.
“Prokarium is uniquely positioned in the biotech landscape with a compelling lead program targeting an underserved population of bladder cancer patients,” stated Henry, "and beyond the immediate value of this program, Prokarium’s Living Cures platform has the potential to be a game-changer in the field of immunotherapy, enabling a new generation of highly innovative, off-the-shelf programmable therapeutics.”
“I’m excited to welcome Dara to our team during this transformative phase, as Prokarium enters clinical development, solidifying our status as a leader in synthetic biology and immuno-oncology,” said Albright.
About Prokarium
Prokarium is a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments. Prokarium’s lead program, currently advancing in clinical trials for bladder cancer, is redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies that are sustainable, accessible and highly effective. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
The investigational immunotherapy ZH9 is being developed as an intravesical monotherapy treatment for the prevention of recurrences in bladder cancer. The PARADIGM-1 study is expected to enroll in H1 2024 across multiple centers in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231102543739/en/
Contact information
Lisa Stone
Investor Relations
lisa.stone@prokarium.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries LLC and Macquarie Group Announce Marketing Agreement for Low Carbon Methanol Project in Sinaloa, Mexico11.12.2023 15:13:00 CET | Press release
Transition Industries LLC announced at COP 28 that it has entered into a Master Services and Marketing Agreement (MSMA) with Macquarie Commodities Trading, an affiliate of Macquarie Group’s Commodities and Global Markets business (“Macquarie” / “CGM”), for its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico (“Pacifico Mexinol” or the “Project”). When it commences operations, Pacifico Mexinol is expected to be one of the largest single low carbon chemicals facilities in the world - producing approximately 300,000 MT of green methanol from captured carbon and green hydrogen and 1.8 million MT of blue methanol per year from natural gas with carbon capture. Under the terms of the MSMA, Macquarie is responsible for marketing all the production from Pacifico Mexinol to customers on a global basis in accordance with methanol offtake agreements, the provisioning of financial hedging services as required by the Project, and supporting
SLB Collaborates with Northern Lights JV and Microsoft to Digitalize Carbon Capture and Storage Value Chain11.12.2023 15:00:00 CET | Press release
SLB (NYSE: SLB) and Northern Lights Joint Venture (NL) announced today they have signed a memorandum of understanding (MoU) with Microsoft to optimize integrated cloud-based workflows for the operation of Northern Lights, one of the first CO2 transport and storage providers for cross-border carbon capture and storage (CCS). The collaboration will contribute to the development of scalable and cost-efficient digital solutions for the emerging CCS industry. “Digital workflows are a key component to successfully managing CO2 through the end-to-end value chain, from capture point to permanent storage. Northern Lights is very pleased to partner with industry leading tech companies, SLB and Microsoft, on the development of digital CCS solutions”, said Børre Jacobsen, Managing Director of Northern Lights. In the initial phases of the collaboration, SLB will extend its digital CCS workflows and numerical simulation systems on its Delfi™ digital platform, which was deployed to streamline the sub
New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life11.12.2023 15:00:00 CET | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analysed baseline data collected prior to initiation of study treatment and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS). “CTCL is a chronic, life-long condition. Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors. “The data provide new insights into the burdens of living with CTC
Battery Manufacturer Hithium Opens New 28 GWh Intelligent Production Plant11.12.2023 15:00:00 CET | Press release
Stationary energy storage expert Hithium will release 28 GWh planned production capacity successively at first stage of Phase 1 of its new base in Chongqing, China. The new plant is designed in line with "Intelligent Manufacturing 4.0" standards, including a 26% increase in automation over the typical "Intelligent Manufacturing 3.0" production system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211098435/en/ Hithium Chongqing production plant (Photo: Business Wire) Hithium’s automation gains at Chongqing have resulted in an overall efficiency jump of 30%, as well as cost reductions amounting to a quarter of production overhead, delivering a significant lead in manufacturing competitiveness. Built with an investment of RMB13 billion ($1.8 billion), the site covers 800,000 m2 and is located in the Tongliang high-tech zone. The new capacity aims at helping to meet global demand for what is expected to be 720GW of energy s
BIO KOREA 2024 Opens for Program Registration and Exhibition Applications11.12.2023 15:00:00 CET | Press release
BIO KOREA 2024, jointly hosted by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), commenced entry registration and exhibition participating company recruitment from December 4, 2023. The event will be held at COEX in Seoul, Korea from May 8th to 10th, 2024. BIO KOREA, marking its 19th edition in 2024, has established itself as the preeminent bio-industry event in Korea. For the past 18 years, BIO KOREA has served as a catalyst for business revitalization and technological exchange between domestic and foreign companies, fostering a vibrant ecosystem of innovation and collaboration within the biohealth sector. Held in May of this year, BIO KOREA 2023 witnessed the participation of approximately 29,400 individuals from 780 companies across 51 countries, resulting in around 1,300 business meetings. Additionally, approximately 330 companies from 18 countries showcased their technologies through approximately